AP2960A - Substituted pyrimidines for the treatment of diseases such as cancer - Google Patents
Substituted pyrimidines for the treatment of diseases such as cancerInfo
- Publication number
- AP2960A AP2960A AP2011005706A AP2011005706A AP2960A AP 2960 A AP2960 A AP 2960A AP 2011005706 A AP2011005706 A AP 2011005706A AP 2011005706 A AP2011005706 A AP 2011005706A AP 2960 A AP2960 A AP 2960A
- Authority
- AP
- ARIPO
- Prior art keywords
- cancer
- diseases
- treatment
- substituted pyrimidines
- pyrimidines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08169807 | 2008-11-24 | ||
| EP09169654 | 2009-09-07 | ||
| PCT/EP2009/065768 WO2010058032A2 (en) | 2008-11-24 | 2009-11-24 | New compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2011005706A0 AP2011005706A0 (en) | 2011-06-30 |
| AP2960A true AP2960A (en) | 2014-08-31 |
Family
ID=42115425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2011005706A AP2960A (en) | 2008-11-24 | 2009-11-24 | Substituted pyrimidines for the treatment of diseases such as cancer |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US8846689B2 (es) |
| EP (1) | EP2367800B9 (es) |
| JP (1) | JP5622740B2 (es) |
| KR (1) | KR101710058B1 (es) |
| CN (2) | CN102292322B (es) |
| AP (1) | AP2960A (es) |
| AR (1) | AR074210A1 (es) |
| AU (1) | AU2009317170B2 (es) |
| BR (1) | BRPI0922801B1 (es) |
| CA (1) | CA2744351C (es) |
| CL (1) | CL2011001215A1 (es) |
| CO (1) | CO6511283A2 (es) |
| EA (1) | EA021997B1 (es) |
| EC (1) | ECSP11011079A (es) |
| ES (1) | ES2664499T3 (es) |
| GE (1) | GEP20146072B (es) |
| HK (1) | HK1160841A1 (es) |
| IL (1) | IL212814B (es) |
| MA (1) | MA32811B1 (es) |
| MX (1) | MX337116B (es) |
| MY (1) | MY176944A (es) |
| NZ (1) | NZ592925A (es) |
| PE (1) | PE20120034A1 (es) |
| TN (1) | TN2011000259A1 (es) |
| TW (1) | TWI491605B (es) |
| UY (1) | UY32259A (es) |
| WO (1) | WO2010058032A2 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI491605B (zh) | 2008-11-24 | 2015-07-11 | Boehringer Ingelheim Int | 新穎化合物 |
| AR074209A1 (es) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina utiles para el tratamiento del cancer |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| JP5539518B2 (ja) | 2009-08-14 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ２−アミノ−５−トリフルオロメチルピリミジン誘導体の位置選択的調製 |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| CA2827172C (en) | 2011-02-17 | 2019-02-26 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
| US20130324532A1 (en) * | 2011-02-17 | 2013-12-05 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| US9187453B2 (en) | 2012-03-28 | 2015-11-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3586835B1 (en) | 2013-09-09 | 2023-11-22 | Peloton Therapeutics, Inc. | Pharmaceutical compositions comprising aryl ethers |
| WO2016144825A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
| US10155726B2 (en) | 2015-03-11 | 2018-12-18 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
| WO2016145045A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions for use in treating glioblastoma |
| US10278942B2 (en) | 2015-03-11 | 2019-05-07 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
| US10335388B2 (en) | 2015-04-17 | 2019-07-02 | Peloton Therapeutics, Inc. | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
| US20170066778A1 (en) * | 2015-09-04 | 2017-03-09 | Aunova Medchem LLC | Solubility for target compounds |
| PE20221259A1 (es) | 2019-11-18 | 2022-08-16 | Inxmed Nanjing Co Ltd | Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras |
| PE20230180A1 (es) | 2019-11-28 | 2023-02-01 | Inxmed Nanjing Co Ltd | Uso de bi853520 en tratamiento contra el cancer |
| CN115052603B (zh) | 2020-02-05 | 2023-12-19 | 应世生物科技(南京)有限公司 | Bi853520与化疗药物的联用 |
| PE20231303A1 (es) * | 2020-08-03 | 2023-08-24 | Inxmed Nanjing Co Ltd | Forma solida de compuesto |
| WO2023020291A1 (zh) * | 2021-08-16 | 2023-02-23 | 应世生物科技(南京)有限公司 | In10018与pld的联用 |
| CN118369120A (zh) | 2021-12-10 | 2024-07-19 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| CA3238851A1 (en) | 2021-12-21 | 2023-06-29 | Yuli Xie | Compound as fak inhibitor and use thereof |
| AU2023224815A1 (en) | 2022-02-28 | 2024-09-26 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Compound as fak inhibitor and use thereof |
| WO2023246869A1 (zh) * | 2022-06-24 | 2023-12-28 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
| CN117462553A (zh) * | 2022-07-20 | 2024-01-30 | 益方生物科技(上海)股份有限公司 | 药物组合产品以及组合疗法 |
| WO2024041527A1 (zh) * | 2022-08-24 | 2024-02-29 | 应世生物科技(南京)有限公司 | Fak抑制剂及微管抑制剂的药物组合及用途 |
| CN118580221A (zh) * | 2023-03-02 | 2024-09-03 | 应世生物科技(南京)有限公司 | 化合物的固体形式 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001064655A1 (en) * | 2000-03-01 | 2001-09-07 | Astrazeneca Ab | 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
| WO2006021457A2 (en) * | 2004-08-27 | 2006-03-02 | Novartis Ag | Pyrimidine derivatives |
| US20080255172A1 (en) * | 2007-04-16 | 2008-10-16 | Hutchison Medipharma Enterprises Limeted | Pyrimidine derivatives |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| AU5438299A (en) | 1998-08-29 | 2000-03-21 | Astrazeneca Ab | Pyrimidine compounds |
| US6906067B2 (en) * | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
| GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004888D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| DE50212771D1 (de) | 2001-10-17 | 2008-10-23 | Boehringer Ingelheim Pharma | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| EA200500721A1 (ru) | 2002-11-28 | 2005-12-29 | Шеринг Акциенгезельшафт | Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств |
| JP4634367B2 (ja) | 2003-02-20 | 2011-02-16 | スミスクライン ビーチャム コーポレーション | ピリミジン化合物 |
| CL2004000306A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US7504396B2 (en) * | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| CA2533320A1 (en) | 2003-08-15 | 2006-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| EP1598343A1 (de) | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
| US7521457B2 (en) * | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| TW200626560A (en) | 2004-09-30 | 2006-08-01 | Tibotec Pharm Ltd | HIV inhibiting 5-carbo-or heterocyclic substituted pyrimidines |
| US20080085901A1 (en) | 2005-01-14 | 2008-04-10 | Neurogen Corporation | Heteroaryl Substituted Quinolin-4-Ylamine Analogues |
| US20070032514A1 (en) | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| US20090149467A1 (en) * | 2005-09-15 | 2009-06-11 | Merck & Co., Inc. | Tyrosine Kinase Inhibitors |
| WO2007120339A1 (en) * | 2005-12-19 | 2007-10-25 | Genentech, Inc. | Pyrimidine kinase inhibitors |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| US7569561B2 (en) | 2006-02-22 | 2009-08-04 | Boehringer Ingelheim International Gmbh | 2,4-diaminopyrimidines useful for treating cell proliferation diseases |
| US7507737B2 (en) | 2006-03-31 | 2009-03-24 | Janssen Pharmaceutica, N.V. | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4receptor |
| GB0619343D0 (en) | 2006-09-30 | 2006-11-08 | Vernalis R&D Ltd | New chemical compounds |
| WO2008040951A1 (en) | 2006-10-03 | 2008-04-10 | Astrazeneca Ab | Compounds |
| KR101475091B1 (ko) | 2006-12-13 | 2014-12-22 | 에프. 호프만-라 로슈 아게 | 비뉴클레오시드 역전사 효소 억제제로서 2-(피페리딘-4-일)-4-페녹시- 또는 페닐아미노-피리미딘 유도체 |
| CN101563327A (zh) | 2006-12-19 | 2009-10-21 | 健泰科生物技术公司 | 嘧啶类激酶抑制剂 |
| AU2008210266B2 (en) * | 2007-01-31 | 2013-09-05 | Ym Biosciences Australia Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
| WO2009115583A1 (en) | 2008-03-20 | 2009-09-24 | Boehringer Ingelheim International Gmbh | Regioselective preparation of substituted pyrimidines |
| SG10201510696RA (en) | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
| TWI491605B (zh) | 2008-11-24 | 2015-07-11 | Boehringer Ingelheim Int | 新穎化合物 |
| AR074209A1 (es) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina utiles para el tratamiento del cancer |
| ES2659725T3 (es) | 2009-05-05 | 2018-03-19 | Dana-Farber Cancer Institute, Inc. | Inhibidores de EGFR y procedimiento de tratamiento de trastornos |
-
2009
- 2009-11-23 TW TW098139766A patent/TWI491605B/zh active
- 2009-11-23 AR ARP090104511A patent/AR074210A1/es not_active Application Discontinuation
- 2009-11-24 EA EA201100794A patent/EA021997B1/ru not_active IP Right Cessation
- 2009-11-24 CA CA2744351A patent/CA2744351C/en active Active
- 2009-11-24 CN CN200980155031.1A patent/CN102292322B/zh active Active
- 2009-11-24 WO PCT/EP2009/065768 patent/WO2010058032A2/en active Application Filing
- 2009-11-24 AU AU2009317170A patent/AU2009317170B2/en active Active
- 2009-11-24 MX MX2011005420A patent/MX337116B/es active IP Right Grant
- 2009-11-24 KR KR1020117014264A patent/KR101710058B1/ko active IP Right Grant
- 2009-11-24 BR BRPI0922801-2A patent/BRPI0922801B1/pt active IP Right Grant
- 2009-11-24 PE PE2011001080A patent/PE20120034A1/es active IP Right Grant
- 2009-11-24 ES ES09756513.9T patent/ES2664499T3/es active Active
- 2009-11-24 GE GEAP200912270A patent/GEP20146072B/en unknown
- 2009-11-24 NZ NZ592925A patent/NZ592925A/xx unknown
- 2009-11-24 UY UY0001032259A patent/UY32259A/es not_active Application Discontinuation
- 2009-11-24 EP EP09756513.9A patent/EP2367800B9/en active Active
- 2009-11-24 JP JP2011536901A patent/JP5622740B2/ja active Active
- 2009-11-24 MY MYPI2011002290A patent/MY176944A/en unknown
- 2009-11-24 CN CN201410635154.8A patent/CN104478865B/zh active Active
- 2009-11-24 AP AP2011005706A patent/AP2960A/xx active
- 2009-11-24 US US13/130,669 patent/US8846689B2/en active Active
-
2011
- 2011-05-11 IL IL212814A patent/IL212814B/en active IP Right Grant
- 2011-05-20 MA MA33866A patent/MA32811B1/fr unknown
- 2011-05-20 TN TN2011000259A patent/TN2011000259A1/fr unknown
- 2011-05-24 EC EC2011011079A patent/ECSP11011079A/es unknown
- 2011-05-24 CL CL2011001215A patent/CL2011001215A1/es unknown
- 2011-05-24 CO CO11063881A patent/CO6511283A2/es not_active Application Discontinuation
-
2012
- 2012-02-07 HK HK12101136.9A patent/HK1160841A1/zh unknown
-
2014
- 2014-08-29 US US14/472,627 patent/US20140371205A1/en not_active Abandoned
-
2015
- 2015-09-04 US US14/845,529 patent/US20150376141A1/en not_active Abandoned
-
2016
- 2016-08-24 US US15/245,854 patent/US9676762B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001064655A1 (en) * | 2000-03-01 | 2001-09-07 | Astrazeneca Ab | 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
| WO2006021457A2 (en) * | 2004-08-27 | 2006-03-02 | Novartis Ag | Pyrimidine derivatives |
| US20080255172A1 (en) * | 2007-04-16 | 2008-10-16 | Hutchison Medipharma Enterprises Limeted | Pyrimidine derivatives |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2960A (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
| IL214746A0 (en) | Substituted pyrimidines for the treatment of cancer | |
| LT2303021T (lt) | Junginiai, skirti vėžio gydymui | |
| HK1154382A1 (en) | Triazole derivatives useful for the treatment of diseases | |
| ZA200906210B (en) | 3-Imidazolyl-Indoles for the treatment of proliferative diseases | |
| EP2365815A4 (en) | EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| ZA201101899B (en) | Bicyclic triazole derivatives for the treatment of tumours | |
| ZA201107879B (en) | Composition for the treatment of prostate cancer | |
| IL208357A0 (en) | Spiro-indole derivatives for the treatment of parasitic diseases | |
| IL213761A0 (en) | Novel ortho-aminoamides for the treatment of cancer | |
| EP2331520A4 (en) | ROSAMINE DERIVATIVES AS AGENTS FOR CANCER TREATMENT | |
| ZA201003425B (en) | 5-cyano-thienopyridines for the treatment of tumors | |
| IL201449A0 (en) | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | |
| IL210066A0 (en) | Novel ortho-aminoanilides for the treatment of cancer | |
| EP2331130A4 (en) | IGE ANTIBODIES FOR THE TREATMENT OF CANCER | |
| IL220134A0 (en) | Thiazole derivatives for the treatment of diseases such as cancer | |
| ZA201007729B (en) | Use of corticotropin-releasing factor for the treatment of cancer | |
| AP2011005893A0 (en) | Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer. | |
| EP2214485A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| GB0712513D0 (en) | Treatment of cancer | |
| GB0817056D0 (en) | Polypeptide for treatment of cancer | |
| GB0604114D0 (en) | Combinations for the treatment of cancer |